SCYNEXIS Announces Submission of New Drug Application to the U.S. Food and Drug Administration for Oral Ibrexafungerp for the Treatment of Vaginal Yeast Infection Oct 14, 2020
SCYNEXIS to Present Two Posters Highlighting Ibrexafungerp for the Treatment of Vaginal Yeast Infection at the 23rd Annual Premier Women's Healthcare Virtual Conference Oct 12, 2020
SCYNEXIS Announces Presentations at 2020 IDSOG Virtual Annual Meeting Highlighting Ibrexafungerp’s Potential for the Treatment of Vulvovaginal Candidiasis Aug 13, 2020
SCYNEXIS Reports Successful Completion of Pre-NDA Meetings with the FDA Regarding Ibrexafungerp for the Treatment of Vulvovaginal Candidiasis Jul 29, 2020
SCYNEXIS Announces Four Posters Presented at ASM Microbe 2020 Highlighting the Potential Clinical Utility of Ibrexafungerp Jul 22, 2020
SCYNEXIS to Host A Key Opinion Leader Discussion on the Immediate Need in Treating Women with Vaginal Yeast Infections Jul 9, 2020
